Nabiximols
Nabiximols is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
1435 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 14 | 1 | 1 | 16 |
| Sclerosis | D012598 | — | — | — | — | 13 | 1 | — | 14 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 5 | 6 | 1 | 1 | 13 |
| Muscle spasticity | D009128 | — | — | — | 1 | 9 | 1 | — | 11 |
| Seizures | D012640 | — | G40.4 | — | — | 4 | 3 | 2 | 9 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | 1 | 4 | 2 | 1 | 8 |
| Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 3 | 3 | 1 | 7 |
| Tuberous sclerosis | D014402 | — | Q85.1 | — | — | 3 | 2 | 1 | 6 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
| Behavior | D001519 | GO_0007610 | STY/T053 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | 14 | — | — | 14 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | 5 | — | 1 | 8 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 5 | — | 1 | 6 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | 5 | — | — | 5 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | 3 | — | — | 3 |
| Cancer pain | D000072716 | — | G89.3 | — | — | 2 | — | — | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | 2 | 1 | — | — | 2 |
| Hyperalgesia | D006930 | — | — | — | — | 2 | — | — | 2 |
| Rett syndrome | D015518 | Orphanet_778 | F84.2 | — | — | 2 | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 3 | — | — | — | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | — | 1 | 3 |
| Autism spectrum disorder | D000067877 | — | F84.0 | — | 2 | — | — | — | 2 |
| Sturge-weber syndrome | D013341 | Orphanet_3205 | Q85.89 | 1 | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Cannabis | D002188 | — | — | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Drug resistant epilepsy | D000069279 | — | — | 1 | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | — | G96.9 | — | — | — | — | 1 | 1 |
| Brain diseases | D001927 | — | G93.40 | — | — | — | — | 1 | 1 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nabiximols |
| INN | _ |
| Description | Nabiximols (USAN, trade name Sativex) is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. In 2019, it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract. Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.
|
| Classification | Small molecule |
| Drug class | cannabinol derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 56575-23-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3833333 |
| ChEBI ID | — |
| PubChem CID | 44148067 |
| DrugBank | — |
| UNII ID | K4H93P747O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
202 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use